Amylin (AMLN) Said No More Than Two Dissident Directors Elected
More News related to AMLN
- Notable Analyst Rating Changes 11/24: ABG, PRU, RS, AYI, AMLN, TLAB Upgraded; DELL, CIEN, UNP, ALV Downgraded
- Amylin Pharmaceuticals (AMLN): Upgraded to Overweight at Barclays, target raised to $22
- Barclays Upgrades Amylin Pharmaceuticals (AMLN) to Overweight
- Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
- Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDA's BYETTA(R) (Exenatide) Injection Update
More News related to Corporate News
- Regent Communications (RGCI) Receives Delisting Notification From NASDAQ
- Emclaire Financial (EMCF) to Withdraw $20M Common Offerin; Cites Unfavorable Market Conditions
- Swine Flu Cases Decline to Lowest Level in 2+ Months
- Tri-Valley Corp. (TIV) Will Stay on NYSE AMEX, Deficiency Resolved
- Phoenix Footwear (PXG) Enters into $4.5M Secured Revolving Credit Facility
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) confirmed that no more than two of the five dissident nominees (one independent nominee from Eastbourne Capital Management, L.L.C. and one nominee from Carl Icahn) have been elected to Amylin's Board.
Additionally, Mr. Icahn's proposal to reincorporate the Company from Delaware to North Dakota has been defeated.
Related Categories
Corporate NewsStocks Mentioned
-0.17Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
